SALT LAKE CITY, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in precision medicine, announced that its Myriad Autoimmune business unit will present new data ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The Vectra multi-biomarker disease score, ...

New data has demonstrated an association between high Vectra DA scores and an increased risk of joint damage progression in patients with rheumatoid arthritis. On Wednesday at the European League ...

SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today ...

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new ...

Myriad Genetics, Inc. MYGN is in the process of presenting favorable data related to the Vectra test, as part of its Autoimmune business, at the on-going 2019 ACR/ARP Annual Meeting in Atlanta, GA.

The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline. Starting Sunday, Crescendo Bioscience will present a series of abstracts on its Vectra ...